Paper Details

  1. Home
  2. Paper Details

Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.

Author: ChaDae Ryong, HanByoung Geun, HanSang Youb, JangYounghwan, JeongKyung Hwan, JoYoung-Il, KangShin-Wook, KangSun Woo, KimBogyeong, KimNam-Ho, KimSung Gyun, NaKi-Ryang, OhKook-Hwan, ParkHyeong Cheon, ParkSun-Hee, ShinSeonghye, YoonSun Ae

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Gemigliptin and linagliptin did not differ with respect to safety and efficacy in patients with T2DM and renal impairment.
Paper Details　
Original Abstract of the Article :
AIMS: The long-term safety and efficacy of gemigliptin was evaluated in the present extension study after a 12-week study during a 40-week follow-up period. METHODS: The main study was a randomized, placebo-controlled, double-blinded, phase IIIb study in which 50 mg of gemigliptin (N = 66) or place...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/dom.13059

データ提供：米国国立医学図書館（NLM）

Gemigliptin and Linagliptin: A Head-to-Head Comparison in Type 2 Diabetes

Diabetes research is constantly evolving, seeking innovative treatments for type 2 diabetes, especially for patients with kidney impairment. This study investigates the long-term efficacy and safety of gemigliptin compared to linagliptin in patients with type 2 diabetes and renal impairment. Both drugs are DPP-4 inhibitors, a class of medications used to control blood sugar levels. The study utilized a randomized, controlled design to evaluate the effectiveness of each drug over a 40-week period.

Similar Effectiveness, Similar Safety

The study revealed that both gemigliptin and linagliptin demonstrated comparable effectiveness in lowering blood sugar levels and had similar safety profiles. While both drugs showed a significant reduction in HbA1c levels, there was no significant difference between the two groups. The findings suggest that both medications are safe and effective options for managing type 2 diabetes in patients with renal impairment.

Navigating Diabetes Management

The research emphasizes the importance of individualized treatment approaches for type 2 diabetes. It provides valuable insights for healthcare professionals when choosing medication for patients with renal impairment. While both gemigliptin and linagliptin appear to be effective options, further research is needed to determine the optimal choice for individual patients. It's like choosing the right path in a desert - each path may lead to the destination but some may be more challenging than others.

Dr.Camel's Conclusion

Navigating the vast desert of diabetes treatment options can be challenging, especially for patients with renal impairment. This research sheds light on the effectiveness and safety of gemigliptin and linagliptin, offering valuable insights for healthcare professionals. While the study found similar effectiveness for both medications, further investigation is needed to identify the best path for each individual. Just like a desert traveler, finding the perfect oasis for diabetes management requires a personalized approach.

Date :
  1. Date Completed 2018-12-27
  2. Date Revised 2018-12-27
Further Info :

Pubmed ID

28719008

DOI: Digital Object Identifier

10.1111/dom.13059

Related Literature

Article Analysis
・Side Effects of linagliptin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.